Base de dados : MEDLINE
Pesquisa : C08.618.085 [Categoria DeCS]
Referências encontradas : 6268 [refinar]
Mostrando: 1 .. 10   no formato [Detalhado]

página 1 de 627 ir para página                         

  1 / 6268 MEDLINE  
              next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29386437
[Au] Autor:Nagasato A; Nakamura M; Kamimura H
[Ad] Endereço:Department of Pharmaceutical and Health Care Management, Faculty of Pharmaceutical Sciences, Fukuoka University.
[Ti] Título:[Comparative Study of the Efficacy and Safety of Caffeine and Aminophylline for the Treatment of Apnea in Preterm Infants].
[So] Source:Yakugaku Zasshi;138(2):237-242, 2018.
[Is] ISSN:1347-5231
[Cp] País de publicação:Japan
[La] Idioma:jpn
[Ab] Resumo: Methylxanthine is widely administered for the treatment of apnea of prematurity in many countries, and previous reports have clearly established that caffeine is effective for the treatment of apnea of prematurity. In Japan, caffeine has been available since December 2014. Thus, we compared the efficacy and safety of caffeine with that of aminophylline in our hospital. There was no significant difference between the caffeine group and aminophylline group regarding the characteristics of the study patients. The mean efficacy rate from day 1 to day 10 was 89.5% in the caffeine group, and 81.9% in the aminophylline group, although the rate of improvement in apnea episodes each day from day 1 to day 10 was not significantly different between the two groups. On the other hand, the adverse event rates in the caffeine group and the aminophylline group were 70.6% and 75.0%, respectively. No significant difference was observed in the adverse event rates between the two groups. Moreover, suspected abdominal distension due to the drug administration was more frequently observed with the aminophylline group. Our findings indicate that caffeine is as effective as aminophylline, while it is superior to aminophylline regarding its overall safety.
[Mh] Termos MeSH primário: Aminofilina/administração & dosagem
Apneia/tratamento farmacológico
Cafeína/administração & dosagem
Recém-Nascido Prematuro
[Mh] Termos MeSH secundário: Administração Oral
Aminofilina/efeitos adversos
Apneia/etiologia
Cafeína/efeitos adversos
Feminino
Seres Humanos
Recém-Nascido
Infusões Intravenosas
Masculino
Segurança
Resultado do Tratamento
[Pt] Tipo de publicação:COMPARATIVE STUDY; JOURNAL ARTICLE
[Nm] Nome de substância:
27Y3KJK423 (Aminophylline); 3G6A5W338E (Caffeine)
[Em] Mês de entrada:1802
[Cu] Atualização por classe:180228
[Lr] Data última revisão:
180228
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:180202
[St] Status:MEDLINE
[do] DOI:10.1248/yakushi.17-00144


  2 / 6268 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
[PMID]:28450776
[Au] Autor:Tolesa K; Gebreal GW
[Ad] Endereço:Department of Ophthalmology, Jimma University, Ethiopia.
[Ti] Título:Brainstem Anesthesia after Retrobulbar Block: A Case Report and Review of Literature.
[So] Source:Ethiop J Health Sci;26(6):589-594, 2016 Nov.
[Is] ISSN:2413-7170
[Cp] País de publicação:Ethiopia
[La] Idioma:eng
[Ab] Resumo:BACKGROUND: Retro-bulbar anesthesia is one of the most common regional blocks used for intraocular surgeries. Complications associated with regional blocks may be limited to the eye or may be systemic. CASE REPORT: After a retro-bulbar block for glaucoma surgery, a 60-year-old man developed loss of consciousness, apnea with hypotension and bradycardia-features of brainstem anesthesia. We present the clinical features, treatment and comments on how to prevent the problem as well as a review of the literature on reported cases. CONCLUSION: Although it is rare, treating physicians should be aware of the potentially lethal consequences of retro-bulbar block, understand measures to reduce the risks and early recognition and treatment. Facilities where ophthalmic surgeries are performed under local anesthesia should be properly equipped and staffed for advanced resuscitation.
[Mh] Termos MeSH primário: Anestésicos Locais/efeitos adversos
Tronco Encefálico/efeitos dos fármacos
Bupivacaína/efeitos adversos
Trabeculectomia/efeitos adversos
[Mh] Termos MeSH secundário: Anestésicos Locais/administração & dosagem
Apneia/induzido quimicamente
Bupivacaína/administração & dosagem
Glaucoma/cirurgia
Seres Humanos
Hipotensão/induzido quimicamente
Masculino
Meia-Idade
Trabeculectomia/métodos
Inconsciência/induzido quimicamente
[Pt] Tipo de publicação:CASE REPORTS; JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Anesthetics, Local); Y8335394RO (Bupivacaine)
[Em] Mês de entrada:1802
[Cu] Atualização por classe:180205
[Lr] Data última revisão:
180205
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170429
[St] Status:MEDLINE


  3 / 6268 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29173321
[Au] Autor:Koch G; Datta AN; Jost K; Schulzke SM; van den Anker J; Pfister M
[Ad] Endereço:Pediatric Pharmacology and Pharmacometrics Research, University of Basel Children's Hospital (UKBB), Basel, Switzerland. Electronic address: gilbert.koch@ukbb.ch.
[Ti] Título:Caffeine Citrate Dosing Adjustments to Assure Stable Caffeine Concentrations in Preterm Neonates.
[So] Source:J Pediatr;191:50-56.e1, 2017 Dec.
[Is] ISSN:1097-6833
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:OBJECTIVE: To identify dosing strategies that will assure stable caffeine concentrations in preterm neonates despite changing caffeine clearance during the first 8 weeks of life. METHODS: A 3-step simulation approach was used to compute caffeine doses that would achieve stable caffeine concentrations in the first 8 weeks after birth: (1) a mathematical weight change model was developed based on published weight distribution data; (2) a pharmacokinetic model was developed based on published models that accounts for individual body weight, postnatal, and gestational age on caffeine clearance and volume of distribution; and (3) caffeine concentrations were simulated for different dosing regimens. RESULTS: A standard dosing regimen of caffeine citrate (using a 20 mg/kg loading dose and 5 mg/kg/day maintenance dose) is associated with a maximal trough caffeine concentration of 15 mg/L after 1 week of treatment. However, trough concentrations subsequently exhibit a clinically relevant decrease because of increasing clearance. Model-based simulations indicate that an adjusted maintenance dose of 6 mg/kg/day in the second week, 7 mg/kg/day in the third to fourth week and 8 mg/kg/day in the fifth to eighth week assures stable caffeine concentrations with a target trough concentration of 15 mg/L. CONCLUSIONS: To assure stable caffeine concentrations during the first 8 weeks of life, the caffeine citrate maintenance dose needs to be increased by 1 mg/kg every 1-2 weeks. These simple adjustments are expected to maintain exposure to stable caffeine concentrations throughout this important developmental period and might enhance both the short- and long-term beneficial effects of caffeine treatment.
[Mh] Termos MeSH primário: Apneia/tratamento farmacológico
Cafeína/administração & dosagem
Estimulantes do Sistema Nervoso Central/administração & dosagem
Citratos/administração & dosagem
Doenças do Prematuro/tratamento farmacológico
[Mh] Termos MeSH secundário: Peso ao Nascer
Cafeína/farmacocinética
Cafeína/uso terapêutico
Estimulantes do Sistema Nervoso Central/farmacocinética
Estimulantes do Sistema Nervoso Central/uso terapêutico
Citratos/farmacocinética
Citratos/uso terapêutico
Relação Dose-Resposta a Droga
Esquema de Medicação
Monitoramento de Medicamentos
Feminino
Seres Humanos
Lactente
Recém-Nascido
Recém-Nascido Prematuro
Masculino
Ganho de Peso
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Central Nervous System Stimulants); 0 (Citrates); 3G6A5W338E (Caffeine); U26EO4675Q (caffeine citrate)
[Em] Mês de entrada:1712
[Cu] Atualização por classe:171211
[Lr] Data última revisão:
171211
[Sb] Subgrupo de revista:AIM; IM
[Da] Data de entrada para processamento:171128
[St] Status:MEDLINE


  4 / 6268 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28813484
[Au] Autor:Na ES; De Jesús-Cortés H; Martinez-Rivera A; Kabir ZD; Wang J; Ramesh V; Onder Y; Rajadhyaksha AM; Monteggia LM; Pieper AA
[Ad] Endereço:Department of Psychology & Philosophy, Texas Woman's University, Denton, TX, United States of America.
[Ti] Título:D-cycloserine improves synaptic transmission in an animal mode of Rett syndrome.
[So] Source:PLoS One;12(8):e0183026, 2017.
[Is] ISSN:1932-6203
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:Rett syndrome (RTT), a leading cause of intellectual disability in girls, is predominantly caused by mutations in the X-linked gene MECP2. Disruption of Mecp2 in mice recapitulates major features of RTT, including neurobehavioral abnormalities, which can be reversed by re-expression of normal Mecp2. Thus, there is reason to believe that RTT could be amenable to therapeutic intervention throughout the lifespan of patients after the onset of symptoms. A common feature underlying neuropsychiatric disorders, including RTT, is altered synaptic function in the brain. Here, we show that Mecp2tm1.1Jae/y mice display lower presynaptic function as assessed by paired pulse ratio, as well as decreased long term potentiation (LTP) at hippocampal Schaffer-collateral-CA1 synapses. Treatment of Mecp2tm1.1Jae/y mice with D-cycloserine (DCS), an FDA-approved analog of the amino acid D-alanine with antibiotic and glycinergic activity, corrected the presynaptic but not LTP deficit without affecting deficient hippocampal BDNF levels. DCS treatment did, however, partially restore lower BDNF levels in the brain stem and striatum. Thus, treatment with DCS may mitigate the severity of some of the neurobehavioral symptoms experienced by patients with Rett syndrome.
[Mh] Termos MeSH primário: Ciclosserina/farmacologia
Síndrome de Rett/fisiopatologia
Transmissão Sináptica/efeitos dos fármacos
[Mh] Termos MeSH secundário: Animais
Apneia
Tronco Encefálico/metabolismo
Tronco Encefálico/fisiopatologia
Fator Neurotrófico Derivado do Encéfalo/metabolismo
Corpo Estriado/metabolismo
Corpo Estriado/fisiopatologia
Ciclosserina/administração & dosagem
Modelos Animais de Doenças
Marcha/efeitos dos fármacos
Hipocampo/efeitos dos fármacos
Hipocampo/fisiopatologia
Locomoção/efeitos dos fármacos
Masculino
Proteína 2 de Ligação a Metil-CpG/genética
Camundongos
Camundongos Transgênicos
Força Muscular/efeitos dos fármacos
Síndrome de Rett/tratamento farmacológico
Síndrome de Rett/genética
Síndrome de Rett/metabolismo
Tremor
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Brain-Derived Neurotrophic Factor); 0 (Methyl-CpG-Binding Protein 2); 95IK5KI84Z (Cycloserine)
[Em] Mês de entrada:1710
[Cu] Atualização por classe:171018
[Lr] Data última revisão:
171018
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170817
[St] Status:MEDLINE
[do] DOI:10.1371/journal.pone.0183026


  5 / 6268 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28772013
[Au] Autor:Goudarzi M; Yaghooti AA; Marashi S
[Ad] Endereço:Department of Anesthesiology and Critical Care, Tehran University of Medical Sciences, Tehran, Iran.
[Ti] Título:Comment to "Intraoperative apnea in children after buffered 5% povidone-iodine site sterilization for strabismus surgery".
[So] Source:Paediatr Anaesth;27(9):975, 2017 09.
[Is] ISSN:1460-9592
[Cp] País de publicação:France
[La] Idioma:eng
[Mh] Termos MeSH primário: Apneia
Povidona-Iodo
[Mh] Termos MeSH secundário: Anti-Infecciosos Locais
Criança
Seres Humanos
Esterilização
Estrabismo
[Pt] Tipo de publicação:LETTER; COMMENT
[Nm] Nome de substância:
0 (Anti-Infective Agents, Local); 85H0HZU99M (Povidone-Iodine)
[Em] Mês de entrada:1708
[Cu] Atualização por classe:171116
[Lr] Data última revisão:
171116
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170804
[St] Status:MEDLINE
[do] DOI:10.1111/pan.13192


  6 / 6268 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28684195
[Au] Autor:Binks MJ; Holyoak RS; Melhuish TM; Vlok R; Bond E; White LD
[Ad] Endereço:Wagga Wagga Rural Referral Hospital, NSW, Australia; Faculty of Medicine, University of New South Wales, NSW, Australia. Electronic address: m.binks@unsw.edu.au.
[Ti] Título:Apneic oxygenation during intubation in the emergency department and during retrieval: A systematic review and meta-analysis.
[So] Source:Am J Emerg Med;35(10):1542-1546, 2017 Oct.
[Is] ISSN:1532-8171
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:BACKGROUND: Hypoxemia increases the risk of intubation markedly. Such concerns are multiplied in the emergency department (ED) and during retrieval where patients may be unstable, preparation or preoxygenation time limited and the environment uncontrolled. Apneic oxygenation is a promising means of preventing hypoxemia in this setting. AIM: To test the hypothesis that apnoeic oxygenation reduces the incidence of hypoxemia during endotracheal intubation in the ED and during retrieval. METHODS: We undertook a systematic review of six databases for all relevant studies published up to November 2016. Included studies evaluated apneic oxygenation during intubation in the ED and during retrieval. There were no exemptions based on study design. All studies were assessed for level of evidence and risk of bias. The Review Manager 5.3 software was used to perform meta-analysis of the pooled data. RESULTS: Six trials and a total 1822 cases were included for analysis. The study found a significant reduction in the incidence of desaturation (RR=0.76, p=0.002) and critical desaturation (RR=0.51, p=0.01) when apneic oxygenation was implemented. There was also a significant improvement in first pass intubation success rate (RR=1.09, p=0.004). CONCLUSION: Apneic oxygenation may reduce patient hypoxemia during intubation performed in the ED and during retrieval. It also improves intubation first-pass success rate in this setting.
[Mh] Termos MeSH primário: Extubação/métodos
Apneia/terapia
Serviço Hospitalar de Emergência
Hipóxia/prevenção & controle
Intubação Intratraqueal/métodos
Respiração Artificial/métodos
[Mh] Termos MeSH secundário: Seres Humanos
Oxigenoterapia/métodos
[Pt] Tipo de publicação:JOURNAL ARTICLE; META-ANALYSIS; REVIEW
[Em] Mês de entrada:1710
[Cu] Atualização por classe:171012
[Lr] Data última revisão:
171012
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170708
[St] Status:MEDLINE


  7 / 6268 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28654562
[Au] Autor:Ben Jmaa W; Hernández AI; Sutherland MR; Cloutier A; Germain N; Lachance C; Martin B; Lebel MH; Pladys P; Nuyt AM
[Ad] Endereço:From the *Department of Pediatrics, Sainte-Justine University Hospital and Research Center, Université de Montréal, Montreal, QC, Canada; †Inserm U1099 LTSI and Rennes-1 University, Rennes, France; ‡Department of Physiology, Development and Neuroscience, Monash University, Australia; §Department of Pharmacy, Sainte-Justine University Hospital, Université de Montréal, Montreal, QC, Canada; and ¶CHU Rennes, Department of Pediatric, Rennes, France.
[Ti] Título:Cardio-respiratory Events and Inflammatory Response After Primary Immunization in Preterm Infants < 32 Weeks Gestational Age: A Randomized Controlled Study.
[So] Source:Pediatr Infect Dis J;36(10):988-994, 2017 Oct.
[Is] ISSN:1532-0987
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:BACKGROUND: Inflammation may depress respiration in neonates. This study aimed to establish a link between postimmunization inflammation and cardio-respiratory events (CREs). METHODS: Randomized double-blind controlled study of infants born < 32 weeks gestation receiving the 2 months vaccine, which comprised diphtheria and tetanus toxoids and acellular pertussis adsorbed combined with inactivated poliomyelitis vaccines and Haemophilus b conjugate and the pneumococcal conjugate 10-valent vaccines. Infants were randomized to ibuprofen treatment or a placebo group (n = 28/group). C-reactive protein (CRP) and prostaglandins E2 (PgE2) levels were assessed before and after immunization. CREs were recorded for 72 hours. Heart rate variability was assessed by polysomnography. RESULTS: In the placebo group, immunization was associated with significantly increased CRP levels and an increase in CRE (8.6 ± 11.1 before versus 14.0 ± 12.8 after), which did not reach statistical significance (P = 0.08), and no change in PgE2. The increase in CRP was correlated with changes in CRE (r = 0.4: P < 0.05). In the ibuprofen group, immunization significantly increased CRP levels but was not associated with change in CRE (6.7 ± 7.7 before versus 6.8 ± 9.7 after) and PgE2 levels. Comparing the groups, variation in CRE (ΔCRE before versus after immunization) was significantly lower in the ibuprofen group (0.1 ± 7.9 versus 5.4 ± 10.0 ΔCRE; P < 0.05). CONCLUSION: The first immunization of infants born < 32 weeks was associated with an increase in CRP. Ibuprofen treatment significantly attenuated the variation (Δ) in CRE following first immunization in these infants but the current study could not demonstrate an impact on CRP and PgE2 levels. The impact of anti-inflammatory treatment on antigenicity must be evaluated before their clinical use aiming at reducing CRE after immunization in preterm infants.
[Mh] Termos MeSH primário: Imunização/efeitos adversos
Imunização/estatística & dados numéricos
Recém-Nascido Prematuro
Vacinas/efeitos adversos
[Mh] Termos MeSH secundário: Apneia/epidemiologia
Bradicardia/epidemiologia
Proteína C-Reativa/análise
Método Duplo-Cego
Feminino
Idade Gestacional
Seres Humanos
Ibuprofeno/uso terapêutico
Imunização/métodos
Recém-Nascido
Inflamação/epidemiologia
Masculino
Vacinas/administração & dosagem
[Pt] Tipo de publicação:JOURNAL ARTICLE; RANDOMIZED CONTROLLED TRIAL
[Nm] Nome de substância:
0 (Vaccines); 9007-41-4 (C-Reactive Protein); WK2XYI10QM (Ibuprofen)
[Em] Mês de entrada:1709
[Cu] Atualização por classe:170929
[Lr] Data última revisão:
170929
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170628
[St] Status:MEDLINE
[do] DOI:10.1097/INF.0000000000001647


  8 / 6268 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28615326
[Au] Autor:Gao X; Zhao L; Zhuang J; Zang N; Xu F
[Ad] Endereço:Lovelace Respiratory Research Institute, Albuquerque, New Mexico, USA.
[Ti] Título:Prenatal nicotinic exposure prolongs superior laryngeal C-fiber-mediated apnea and bradycardia through enhancing neuronal TRPV1 expression and excitation.
[So] Source:FASEB J;31(10):4325-4334, 2017 Oct.
[Is] ISSN:1530-6860
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:Maternal cigarette smoke, including prenatal nicotinic exposure (PNE), is responsible for sudden infant death syndrome (SIDS). The fatal events of SIDS are characterized by severe bradycardia and life-threatening apneas. Although activation of transient receptor potential vanilloid 1 (TRPV1) of superior laryngeal C fibers (SLCFs) could induce bradycardia and apnea and has been implicated in SIDS pathogenesis, how PNE affects the SLCF-mediated cardiorespiratory responses remains unexplored. Here, we tested the hypothesis that PNE would aggravate the SLCF-mediated apnea and bradycardia up-regulating TRPV1 expression and excitation of laryngeal C neurons in the nodose/jugular (N/J) ganglia. To this end, we compared the following outcomes between control and PNE rat pups at postnatal days 11-14: ) the cardiorespiratory responses to intralaryngeal application of capsaicin (10 µg/ml, 50 µl), a selective stimulant for TRPV1 receptors, in anesthetized preparation; ) immunoreactivity and mRNA of TRPV1 receptors of laryngeal sensory C neurons in the N/J ganglia retrogradely traced by 1,1'-dioctadecyl-3,3,3',3'-tetramethylindocarbocyanine perchlorate; and ) TRPV1 currents and electrophysiological characteristics of these neurons by using whole-cell patch-clamp technique Our results showed that PNE markedly prolonged the apneic response and exacerbated the bradycardic response to intralaryngeal perfusion of capsaicin, which was associated with up-regulation of TRPV1 expression in laryngeal C neurons. In addition, PNE increased the TRPV1 currents, depressed the slow delayed rectifier potassium currents, and increased the resting membrane potential of these neurons. Our results suggest that PNE is capable of aggravating the SLCF-mediated apnea and bradycardia through TRPV1 sensitization and neuronal excitation, which may contribute to the pathogenesis of SIDS.-Gao, X., Zhao, L., Zhuang, J., Zang, N., Xu, F. Prenatal nicotinic exposure prolongs superior laryngeal C-fiber-mediated apnea and bradycardia through enhancing neuronal TRPV1 expression and excitation.
[Mh] Termos MeSH primário: Apneia/metabolismo
Bradicardia/metabolismo
Fibras Nervosas Amielínicas/metabolismo
Nicotina/farmacologia
Células Receptoras Sensoriais/metabolismo
Fumaça/efeitos adversos
Canais de Cátion TRPV/metabolismo
[Mh] Termos MeSH secundário: Animais
Animais Recém-Nascidos
Apneia/induzido quimicamente
Bradicardia/induzido quimicamente
Capsaicina/farmacologia
Modelos Animais de Doenças
Técnicas de Patch-Clamp/métodos
Ratos Sprague-Dawley
Células Receptoras Sensoriais/efeitos dos fármacos
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Smoke); 0 (TRPV Cation Channels); 0 (Trpv1 protein, rat); 6M3C89ZY6R (Nicotine); S07O44R1ZM (Capsaicin)
[Em] Mês de entrada:1710
[Cu] Atualização por classe:171019
[Lr] Data última revisão:
171019
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170616
[St] Status:MEDLINE
[do] DOI:10.1096/fj.201700163R


  9 / 6268 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28514808
[Au] Autor:Guimard A; Zorgati H; Brulaire S; Amiot V; Prieur F; Collomp K
[Ad] Endereço:CIAMS, Univ. Paris-Sud, Université Paris-Saclay, 91405 Orsay Cedex, France.
[Ti] Título:Physiological Dynamic Apnea Responses in Relation to Apnea Capacity in Triathletes.
[So] Source:Int J Sports Med;38(7):521-526, 2017 Jul.
[Is] ISSN:1439-3964
[Cp] País de publicação:Germany
[La] Idioma:eng
[Ab] Resumo:The aim was to assess the cardiac, arterial oxygen saturation, lactate, hormonal and Borg rating of perceived exertion (RPE) responses to acute apnea in relation to apnea capacity in 18 middle-aged triathletes. Subjects were monitored while swimming two 50-m freestyle exercise trials with fins at maximal speed: with normal frequency breathing (NB) and with complete apnea (Ap); the latter was used to assess apnea capacity. The subjects with significant alteration in swimming performance inducing a time increase greater than 2.5% during Ap vs. NB were put in the group: bad apnea capacity (Bad Ap); the others, who showed no significant alteration in performance, were put in the group: Good Ap. Under apnea, both groups showed a decrease in arterial oxygen saturation (p<0.05). In Ap conditions, only Bad Ap had a significant lower maximal heart rate vs. NB (p<0.05), with lower blood lactate (p<0.05) and arm stroke frequency (p<0.01). No change in saliva hormonal concentrations was found during the experiment for both groups, whereas RPE responses were increased in the Good Ap group under Ap vs. NB conditions. In conclusion, a good apnea capacity seems to be associated with lower cardiovascular and metabolic apnea alterations in middle-aged recreationally-trained triathletes.
[Mh] Termos MeSH primário: Apneia/fisiopatologia
Desempenho Atlético/fisiologia
Consumo de Oxigênio/fisiologia
Natação/fisiologia
[Mh] Termos MeSH secundário: Adulto
Atletas
Frequência Cardíaca
Seres Humanos
Ácido Láctico/sangue
Masculino
Oximetria
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
33X04XA5AT (Lactic Acid)
[Em] Mês de entrada:1709
[Cu] Atualização por classe:170918
[Lr] Data última revisão:
170918
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170518
[St] Status:MEDLINE
[do] DOI:10.1055/s-0043-101375


  10 / 6268 MEDLINE  
              first record previous record
seleciona
para imprimir
Fotocópia
[PMID]:28474588
[Au] Autor:Shivakumar M; Jayashree P; Najih M; Lewis LES; Bhat Y R; Kamath A; Shashikala -
[Ad] Endereço:Departments of Pediatrics and *Community Medicine, Women and Child block, Kasturba Hospital, Manipal. Correspondence to: Dr Leslie Edward Simon Lewis, Professor and Unit Head, Neonatal Intensive Care Unit, Department of Pediatrics, Kasturba Hospital, Manipal University Manipal 576 104, India. leslielewis1@gmail.com.
[Ti] Título:Comparative Efficacy and Safety of Caffeine and Aminophylline for Apnea of Prematurity in Preterm (≤34 weeks) Neonates: A Randomized Controlled Trial.
[So] Source:Indian Pediatr;54(4):279-283, 2017 Apr 15.
[Is] ISSN:0974-7559
[Cp] País de publicação:India
[La] Idioma:eng
[Ab] Resumo:OBJECTIVE: To compare the efficacy and safety of standard doses of Caffeine and Aminophylline for Apnea of prematurity. STUDY DESIGN: Randomized controlled trial. SETTING: Tertiary-care referral centre and a teaching institution in Southern India. Trial was conducted from February 2012 to January 2015. PARTICIPANTS: 240 preterm (≤34 wk) neonates with apnea of prematurity. INTERVENTIONS: Neonates randomized into two groups: Caffeine group received loading dose of caffeine citrate (20 mg/kg) followed by 5 mg/kg/day maintenance dose every 24 hour. Aminophylline group received loading dose of Aminophylline - 5 mg/kg and maintenance dose of 1.5 mg/kg 8-hourly. OUTCOME MEASURES: Difference in apneic spells, associated respiratory morbidity, and acute adverse events were assessed. Association of efficacy with therapeutic drug levels was also evaluated. RESULTS: Infants on aminophylline experienced less apnea spells in 4-7 days of therapy (P=0.03). Mean apnea rate and isolated desaturations were similar in 1-3, 4-7 and 8-14 days of therapy. No difference was noted in duration of Neonatal Intensive Care Unit stay and hospital stay. Mean heart rate was significantly high in Aminophylline group (P<0.001). Risk of developing tachycardia was less (RR 0.30; 95% CI range 0.15 to 0.60; P<0.001) in Caffeine- over Aminophylline-treated infants. CONCLUSION: Aminophylline is as effective as caffeine for prevention of apneic spells in preterm neonates; however, dosage optimization needs to be done to reduce toxicity.
[Mh] Termos MeSH primário: Aminofilina/uso terapêutico
Apneia/tratamento farmacológico
Cafeína/uso terapêutico
Doenças do Prematuro/tratamento farmacológico
[Mh] Termos MeSH secundário: Feminino
Seres Humanos
Recém-Nascido
Masculino
[Pt] Tipo de publicação:JOURNAL ARTICLE; RANDOMIZED CONTROLLED TRIAL
[Nm] Nome de substância:
27Y3KJK423 (Aminophylline); 3G6A5W338E (Caffeine)
[Em] Mês de entrada:1706
[Cu] Atualização por classe:170601
[Lr] Data última revisão:
170601
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170506
[St] Status:MEDLINE



página 1 de 627 ir para página                         
   


Refinar a pesquisa
  Base de dados : MEDLINE Formulário avançado   

    Pesquisar no campo  
1  
2
3
 
           



Search engine: iAH v2.6 powered by WWWISIS

BIREME/OPAS/OMS - Centro Latino-Americano e do Caribe de Informação em Ciências da Saúde